ArticleCureus2026
Paraneoplastic Dermatomyositis Preceding Gastroesophageal Junction Adenocarcinoma: A Case Emphasizing the Importance of Early Malignancy Screening.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dermatomyositis (DM) is an idiopathic inflammatory myopathy marked by proximal muscle weakness and pathognomonic rashes such as heliotrope rash and Gottron papules. DM is associated with an increased risk of malignancy compared to the general population, with 15-30% of cases being paraneoplastic. DM-associated malignancies are often diagnosed at late stages, resulting in cancer being a leading cause of death in this condition. Additionally, DM can mask malignancy by presenting with similar symptoms as the inciting cancer, further emphasizing the importance of early, disease-specific cancer screening. We report a 51-year-old woman with refractory DM presenting with muscle weakness, cutaneous lesions, and dysphagia. Lab tests showed elevated creatine kinase, positive ANA, and negative anti-Jo-1; muscle biopsy confirmed DM. Despite treatment for DM, her symptoms persisted. After complaints of worsening dysphagia, subsequent imaging, endoscopy, and biopsy revealed gastroesophageal junction (GEJ) adenocarcinoma. After receiving immunosuppressive treatment, the patient developed Pseudomonas pneumonia. Unable to recover, she rapidly declined and died in mid-April 2025. This case emphasizes the need for early myositis-specific malignancy screening in new-onset DM, particularly when systemic or gastrointestinal symptoms are present. This will enable timely diagnosis and improve patient outcomes. Paraneoplastic DM often carries a more aggressive course, and while gastrointestinal (GI) cancers are highly associated with the disease, association with GEJ adenocarcinoma is rare. A high index of suspicion for malignancy should be maintained in new-onset DM, especially when systemic symptoms are present. Early malignancy screening tailored to myositis-associated malignancies at the time of diagnosis is critical to improve prognosis and facilitate timely intervention in this life-threatening paraneoplastic syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.